Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

Nan Yao Lee, Wei Han Huang, Ko Chung Tsui, Po Ren Hsueh, Wen Chien Ko

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.

Original languageEnglish
Pages (from-to)150-153
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume70
Issue number1
DOIs
Publication statusPublished - 2011 May

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae'. Together they form a unique fingerprint.

Cite this